Évry, France, October 21, 2025 - IntegraGen (FR0010908723 - ALINT - PEA PME eligible)a company specialized in the genomics of cancer and rare genetic diseases, providing interpretable genomic analyses and data for academic and private laboratories, announces the appointment of Bérengère Génin as Managing Director, replacing Bernard Courtieu.

With over 15 years' experience at IntegraGen, Bérengère Génin has held key positions in the company's growth and structuring. After contributing as CTO to the development of the company's entire data and bioinformatics strategy, including the creation of software solutions for the analysis and valorization of genomic data, she continued her career as Sales Director for the OncoDNA group, before being appointed COO of IntegraGen in 2024.

The Board of Directors emphasizes its in-depth knowledge of the company, its ability to combine
technological innovation and strategic vision, as well as its dynamism and commitment to its teams.

"The Board of Directors is delighted to entrust the management of IntegraGen to Bérengère Génin, whose in-depth knowledge of the company and clear vision of its development are major assets for this new stage. Under her leadership, IntegraGen will pursue its mission as a benchmark partner in genomics and precision medicine, serving research and patients alike." - Charles-André Brouwers, Chairman of IntegraGen's Board of Directors.

"I am particularly proud of the confidence the Board has placed in me, and determined to lead IntegraGen into a new stage of its development. Buoyed by the commitment and talent of our employees, we are pursuing our mission to put genomics and data analysis at the heart of clinical trials.
Today, we intend to strengthen our international presence as a central genomics laboratory recognized for its expertise and reliability. Thanks to our CLIA/CAP certification, our expertise in advanced genomic analyses and our cutting-edge bioinformatics solutions, we are ideally positioned to accelerate precision medicine and support clinical innovation", declared Bérengère Génin,.

The Board of Directors would also like to thank Bernard Courtieu for his involvement and his decisive role in the development and recognition of IntegraGen as a leading player in genomics in France.

With this appointment, IntegraGen reaffirms its strategic focus on clinical trials and precision medicine. The company boasts a CLIA/CAP-certified laboratory, recognized expertise in high-throughput sequencing and bioinformatics, and an integrated data management and analysis software offering. Backed by experienced and committed teams, and strong partnerships with academic, hospital and pharmaceutical players, IntegraGen intends to strengthen its position in supporting therapeutic innovations on an international scale. The company will continue to pursue all its operational and research activities in line with its commitments to its customers and partners.

About IntegraGen
IntegraGen specializes in the genomics of cancer and genetic diseases. Backed by highly experienced and qualified teams, IntegraGen is a major player in DNA sequencing services and genomic data interpretation software. The company manages one of the largest NGS laboratories in France and operates for leading research institutes. IntegraGen harnesses the potential of high-throughput sequencing to offer patients the promise of precision medicine. IntegraGen has over 40 employees and generated revenues of 8.5 million euros in 2024.

IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - PEA-PME eligible).

For more information, visit www.integragen.com and follow us on LinkedIn.